US Food and Drug Administration (USFDA) has conducted GMP surveillance Inspection for Zydus Lifesciences' Unit 9 facility located at Zydus Biotech Park, Changodar, Ahmedabad. The inspection was conducted from April 27, 2026 to May 05, 2026. The inspection closed with seven observations. There were no data integrity related observations. The company will closely work with the USFDA to address the observations expeditiously.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
